Ciska van Doesum has over fifteen years’ experience in the pharmaceutical and biotechnology industries. She has joined ISA Pharmaceuticals in 2018, where she is responsible for leading a number of multifunctional development teams and the alliance with Regeneron. Previously she was responsible for the global pre-clinical and early clinical development strategy at ProQR and Astellas. Ciska has been involved in the submission of multiple INDs and three European registrations in the field of pediatric medicine, orphan diseases, ophthalmology, urology, oncology and infectious diseases. Ciska has an MSc in Bio-Pharmaceutical Sciences (University of Leiden), a PhD in Medicine (University of Utrecht) and is a European registered toxicologist (ERT).